NASDAQ:ELDN Eledon Pharmaceuticals Q2 2025 Earnings Report $2.45 -0.05 (-2.00%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$2.46 +0.01 (+0.41%) As of 10/6/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Eledon Pharmaceuticals EPS ResultsActual EPS-$0.13Consensus EPS -$0.23Beat/MissBeat by +$0.10One Year Ago EPSN/AEledon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEledon Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time4:00PM ETUpcoming EarningsEledon Pharmaceuticals' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eledon Pharmaceuticals Earnings HeadlinesEledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual MeetingOctober 5 at 4:05 PM | globenewswire.comEledon Pharmaceuticals, Inc. (ELDN)September 25, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Eledon Pharmaceuticals, Inc. Presents Updated Long-Term Phase 2 BESTOW Extension Study Results For Tegoprubart And Announces FDA Fast Track DesignationSeptember 23, 2026 | marketscreener.comMEledon Shares Rise on Fast-Track Designation for Kidney TreatmentSeptember 22, 2026 | marketscreener.comMEledon rises on new mid-stage trial data, FDA fast track status for lead drugSeptember 22, 2026 | seekingalpha.comSee More Eledon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email. Email Address About Eledon PharmaceuticalsEledon Pharmaceuticals (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on developing therapies for patients with life-threatening autoimmune diseases and those undergoing organ or cell transplantation. The company’s research is centered on the CD40 ligand (CD40L) pathway, an important regulator of immune-system activation. Eledon’s lead product candidate is tegoprubart, an investigational monoclonal antibody designed to block CD40L and reduce harmful immune responses. The company is evaluating tegoprubart in transplant-related settings, including kidney transplantation, as well as in other potential applications involving immune-mediated disease and cell transplantation. The company was formerly known as Novus Therapeutics and adopted the Eledon Pharmaceuticals name as it shifted its strategic focus toward immunology and transplantation. Eledon is headquartered in Irvine, California, and operates primarily through research, clinical development and collaborations related to its therapeutic programs. David de Graaf serves as the company’s president and chief executive officer.View Eledon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
